GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...

Novartis (NYSE:NVS) (OTCPK:NVSEF) announced Thursday the acquisition of Kate Therapeutics, a San Diego-based gene therapy developer, for up to $1.1B. According to the deal terms, the Swiss ...

Cell and gene therapy is the hottest area in biotech at the moment, and Gilead’s $11.9bn acquisition of Kite Pharma in October has been followed by Celgene’s $9bn buyout of Juno Therapeutics.

Meanwhile, Novartis is trying to extend the use of its gene therapy into other forms of SMA (types 2 and 3), adding another 3,000-4,000 patients apiece according to some estimates.

“Despite remarkable outcomes from some gene therapies, there are still improvements needed.” Swiss companies like Roche and Novartis continue to invest in the field, and scientists remain ...

Extensive collaboration between various stakeholders in the field of cell and gene therapies ... global healthcare company Novartis. “Revolutions leading to new therapies, and evolutions to ...